All In Biotech

Drug Trial Radar · NCT02554812

A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)

A PHASE 1B/2 OPEN-LABEL STUDY TO EVALUATE SAFETY, CLINICAL ACTIVITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB (MSB0010718C) IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES

Last checked: Nov 19, 2026Latest source record: Jul 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingRandomized with 409 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

409

Actual

Start

Nov 9, 2015

Primary completion

Mar 23, 2023

Study completion Mar 23, 2023

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Sep 18, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1b/2 dose-optimization study to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of avelumab (MSB0010718C) in combination with other cancer immunotherapies in patients with locally advanced or metastatic solid tumors. The primary purpose is to assess the safety and early signs of efficacy of various avelumab combinations with other cancer immunotherapies, optimizing dosing regimens as appropriate, in a limited series of indications.

Conditions

  • Advanced Cancer

Interventions

  • AvelumabDrug

    Anti-PD-L1 antibody

  • UtomilumabDrug

    Anti-4-1BB antibody

  • PF-04518600Drug

    OX40 Agonist

  • PD 0360324Drug

    Anti-M-CSF

  • CMP-001Drug

    TLR9 agonist

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1b Lead-in: Number of Participants With First 2 Cycles Dose Limiting Toxicity (DLT) for Combination ATime frame: Baseline up to Cycle 2 (up to 8 weeks)
  2. Phase 1b Lead-in: Number of Participants With First 2 Cycles DLT for Combination BTime frame: Baseline up to Cycle 2 (up to 8 weeks)
  3. Phase 1b Lead-in: Number of Participants With First 2 Cycles DLT for Combination CTime frame: Baseline up to Cycle 2 (up to 8 weeks)
  4. Phase 1b Lead-in: Number of Participants With First 2 Cycles DLT for Combination DTime frame: Baseline up to Cycle 2 (up to 8 weeks)
  5. Phase 1b Lead-in: Number of Participants With First Cycle DLT for Combination FTime frame: Baseline up to first Cycle (up to 4 weeks)
  6. Phase 2: Percentage of Participants With Confirmed Objective Response (OR) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 by Investigator Assessment for Combination ATime frame: From start of the treatment until disease progression or death due to any cause, whichever occurred first (maximum up to 53 months approximately)
  7. Phase 2: Percentage of Participants With Confirmed OR as Per RECIST v 1.1 by Investigator Assessment for Combination BTime frame: From start of the treatment until disease progression or death due to any cause, whichever occurred first (approximately 26 months)

Locations

88 sites in 8 countries. Site status is shown where the registry gives one.

  • UCSD Medical Center - Encinitas

    Encinitas, California

  • Koman Family Outpatient Pavilion

    La Jolla, California

  • UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Pavilion)

    La Jolla, California

  • UC San Diego Perlman Medical Offices

    La Jolla, California

  • UC San Diego Moores Cancer Center

    La Jolla, California

  • UCLA Clinical Research Unit (Adminstration Office)

    Los Angeles, California

  • Ronald Reagan UCLA Medical Center

    Los Angeles, California

  • UCLA Hematology-Oncology Clinic

    Los Angeles, California

  • UCLA Hematology-Oncology Infusion Center

    Los Angeles, California

  • UC San Diego Medical Center - Hillcrest

    San Diego, California

  • UCSD Medical Center - Vista

    Vista, California

  • Georgetown University Medical Center

    Washington D.C., District of Columbia

  • Mount Sinai Comprehensive Cancer Center - Aventura

    Aventura, Florida

  • Mount Sinai Comprehensive Cancer Center

    Miami Beach, Florida

  • Florida Cancer Specialists

    Sarasota, Florida

  • H Lee Moffitt Cancer Center and Research Institute

    Tampa, Florida

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa

  • University of Michigan Hospitals

    Ann Arbor, Michigan

  • University of Michigan

    Ann Arbor, Michigan

  • Investigational Pharmacy, Karmanos Cancer Center

    Detroit, Michigan

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Karmanos Cancer Institute Weisberg Cancer Treatment Center

    Farmington Hills, Michigan

  • VA NY Harbor Healthcare System

    New York, New York

  • NYU Investigational Pharmacy

    New York, New York

  • NYU Langone Medical Center

    New York, New York

  • NYU Laura and Isaac Perlmutter Cancer Center

    New York, New York

  • Weill Cornell Medical College

    New York, New York

  • Research Pharmacy #PH#

    New York, New York

  • Weill Cornell Medical College/New York Presbyterian Hospital

    New York, New York

  • Sampson Regional Medical Center

    Clinton, North Carolina

  • Southeastern Medical Oncology Center

    Clinton, North Carolina

  • Southeastern Medical Oncology Center

    Goldsboro, North Carolina

  • Wayne Memorial Hospital

    Goldsboro, North Carolina

  • Onslow Memorial Hospital

    Jacksonville, North Carolina

  • Southeastern Medical Oncology Center

    Jacksonville, North Carolina

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • University of Pittsburgh Cancer Institute

    Pittsburgh, Pennsylvania

  • UPCI Investigational Drug Service

    Pittsburgh, Pennsylvania

  • UPMC Shadyside Hospital

    Pittsburgh, Pennsylvania

  • Rhode Island Hospital

    Providence, Rhode Island

Showing 40 of 88 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.